Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

BACKGROUND: Pemafibrate is a novel, selective peroxisome proliferator‐activated receptor α modulator (SPPARMα). In mice, Pemafibrate improved the histological features of non‐alcoholic steatohepatitis (NASH). In patients with dyslipidaemia, it improved serum alanine aminotransferase (ALT). AIMS: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Atsushi, Eguchi, Yuichiro, Yoneda, Masato, Imajo, Kento, Tamaki, Nobuharu, Suganami, Hideki, Nojima, Toshiaki, Tanigawa, Ryohei, Iizuka, Masakazu, Iida, Yuki, Loomba, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292296/
https://www.ncbi.nlm.nih.gov/pubmed/34528723
http://dx.doi.org/10.1111/apt.16596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292296/
https://www.ncbi.nlm.nih.gov/pubmed/34528723
http://dx.doi.org/10.1111/apt.16596

Ejemplares similares